Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Condition:   Myasthenia Gravis Interventions:   Drug: HBM9161 Injection (680mg);   Drug: HBM9161 Drug Product (340mg) Sponsor:   Harbour BioMed (Guangzhou) Co. Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials